(-)-physostigmine | 1217493-55-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: (-)-physostigmine
• 英文别名: N-methylcarbamic acid [(8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] ester；[(8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-methylcarbamate
• CAS: 1217493-55-4
• 化学式: C₁₅H₂₁N₃O₂
• 分子量: 275.351
• InChiKey: PIJVFDBKTWXHHD-WUJWULDRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  44.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (-)-physostigmine 在 sodium 、 正丁醇 作用下， 反应 0.42h， 生成 (-)-(3aS)-eseroline
  参考文献：
  名称：

  Yu, Qian-Sheng; Schoenenberger, Bernhard; Brossi, Arnold, Heterocycles, 1987, vol. 26, # 5, p. 1271 - 1275

  摘要：

  DOI：

文献信息

• Compounds and compositions for treating infection
  申请人：Chepkwony Paul Kiprono

  公开号：US20090069277A1

  公开（公告）日：2009-03-12

  Compounds from 14 Kenyan plants, including from the root of Dovyalis abyssinica and Clutia robusta have been characterized and isolated, and their uses are disclosed.

  来自14种肯尼亚植物的化合物，包括 Dovyalis abyssinica 和 Clutia robusta 的根部已经被鉴定和分离，它们的用途也被公开了。
• COMPOUNDS AND COMPOSITIONS FOR TREATING INFECTION
  申请人：Chepkwony Paul Kiprono

  公开号：US20120190734A1

  公开（公告）日：2012-07-26

  Compounds from 14 Kenyan plants, including from the root of Dovyalis abyssinica and Clutia robusta have been characterized and isolated, and their uses are disclosed.

  来自14种肯尼亚植物的化合物已经被鉴定和分离，包括来自阿比西尼亚多维亚利斯和强健小簇花的根部，它们的用途已经被披露。
• Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
  申请人：Köster Hubert

  公开号：US20110118136A1

  公开（公告）日：2011-05-19

  Capture compounds and collections thereof and methods using the compounds for the analysis of biomolecules are provided. In particular, collections, compounds and methods are provided for analyzing complex protein mixtures, such as the proteome. The compounds are multifunctional reagents that provide for the separation and isolation of complex protein mixtures. Each compound has the formula: wherein: Z is a trityl derivative; X, the reactivity function, covalently binds to amino acid side chains of proteins; Y, the selectivity function, modulates binding of X to the amino acid side chains in proteins such that X binds to fewer proteins when Y is present than in its absence; and Q permits separation or immobilization of the capture compound. Automated systems for performing the methods also are provided.

  本文提供了捕获化合物和化合物集合以及使用这些化合物进行生物分子分析的方法。特别地，提供了用于分析复杂蛋白质混合物（如蛋白质组）的集合、化合物和方法。这些化合物是多功能试剂，可用于分离和分离复杂蛋白质混合物。每个化合物的公式为：其中：Z是三苯甲基衍生物；X是反应性功能，共价结合到蛋白质的氨基酸侧链上；Y是选择性功能，调节X与蛋白质中氨基酸侧链的结合，使得在Y存在时，X与较少的蛋白质结合，而在Y不存在时，X与更多的蛋白质结合；Q允许分离或固定捕获化合物。本文还提供了用于执行这些方法的自动化系统。
• N-Aminocarbamates related to physostigmine, a process for their preparation and their use as medicaments
  申请人：HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED

  公开号：EP0420140A2

  公开（公告）日：1991-04-03

  The present invention relates to compounds of the formula I, where X is hydrogen, halogen or loweralkyl; and R₁, R₂ and R₃ are each independently hydrogen, loweralkyl, cycloalkyl, arylloweralkyl or aryl, or alternatively the group -NR₂R₃ taken as a whole constitutes R₄ being hydrogen or loweralkyl and a process for their preparation. The compounds of the invention show central cholinergic innervative properties for treating various memory dysfunctions and can, therefore, be used as medicaments.

  本发明涉及式 I 的化合物、 其中 X 是氢、卤素或低级烷基；R₁、R₂ 和 R₃ 各自独立地是氢、低级烷基、环烷基、芳低级烷基或芳基，或作为一个整体的基团 -NR₂R₃ 构成。 R₄为氢或低级烷基的化合物及其制备方法。本发明的化合物具有治疗各种记忆功能障碍的中枢胆碱能抑制特性，因此可用作药物。
• MEDICINAL COMPOSITION FOR TREATING BULIMIA AND DEPRESSION ACCOMPANYING BULIMIA
  申请人：Eisai R&D Management Co., Ltd.

  公开号：EP1938811A1

  公开（公告）日：2008-07-02

  Provided is a pharmaceutical composition for the treatment of bulimia in which a cholinesterase inhibitor is combined with at least one member selected from the group consisting of sibutramine, a pharmacologically acceptable salt thereof, an active metabolite thereof, a prodrug thereof and a solvate thereof. The pharmaceutical composition is useful in treating bulimia and depression arising from bulimia.

  本发明提供了一种用于治疗贪食症的药物组合物，其中胆碱酯酶抑制剂与至少一种选自西布曲明、其药理学上可接受的盐、其活性代谢物、其原药和其溶液组成的组的成员相结合。该药物组合物可用于治疗贪食症和由贪食症引起的抑郁症。